Teva completes acquisition of Allergan generics business
03-08-2016
Photo: Courtesy of Teva
Teva announced yesterday that the Federal Trade Commission (FTC) has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva, Allergan, FTC, anticompetitive, generics, acquisition
